Details of Disease

General Information of Disease (ID: DISYX23I)

Disease Name	Peritoneal cancer
Synonyms	peritoneal neoplasm; peritoneum cancer; peritoneal cavity cancer; peritoneal cancer; malignant peritoneum neoplasm; malignant peritoneal neoplasm; malignant neoplasm of peritoneum; cancer of the peritoneum; cancer of peritoneum
Disease Class	2C51: Peritoneal cancer
Definition	A malignant neoplasm involving the peritoneum
Disease Hierarchy	DISAT1Z9: Advanced cancer DIS2ZMIF: Peritoneal neoplasm DISYX23I: Peritoneal cancer
ICD Code	ICD-11 ICD-11: 2C51.Z
Disease Identifiers	MONDO ID MONDO_0002087 UMLS CUI C0153467 MedGen ID 102270 SNOMED CT ID 363492001

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)

This Disease is Treated as An Indication in 1 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Niraparib Tosylate	DMLPSWQ	Approved	Small molecular drug	[1]
------------------------------------------------------------------------------------

This Disease is Treated as An Indication in 6 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
TRC105	DM1874J	Phase 3	Monoclonal antibody	[2]
8H9 I-131 mab	DMKADUF	Phase 2	Monoclonal antibody	[3]
EGEN-001	DM6L5TR	Phase 2	NA	[4]
Ovarian dendritic cell-based vaccine	DMPYS2L	Phase 1/2	NA	[5]
DMUC-5754A	DMCT4BA	Phase 1	Antibody	[6]
MCY-M11	DMAESQI	Phase 1	CAR-PBMC Cell therapy	[7]
------------------------------------------------------------------------------------


⏷ Show the Full List of 6 Drug(s)

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)

This Disease Is Related to 1 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
BRCA1	OT5BN6VH	Strong	Genetic Variation	[8]
------------------------------------------------------------------------------------

References

1	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2018
2	ClinicalTrials.gov (NCT01727089) Bevacizumab With or Without TRC105 in Treating Patients With Metastatic Kidney Cancer. U.S. National Institutes of Health.
3	ClinicalTrials.gov (NCT00582608) Tumor Detection Using Iodine-131-Labeled Monoclonal Antibody 8H9. U.S. National Institutes of Health.
4	ClinicalTrials.gov (NCT01118052) EGEN-001 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer. U.S. National Institutes ofHealth.
5	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800027639)
6	ClinicalTrials.gov (NCT01335958) Safety and Pharmacokinetics of DMUC5754A Administered Intravenously to Patients With Platinum-Resistant Ovarian Cancer or Unresectable Pancreatic Cancer. U.S. National Institutes of Health.
7	ClinicalTrials.gov (NCT03608618) Intraperitoneal MCY-M11 (Mesothelin-targeting CAR) for Treatment of Advanced Ovarian Cancer and Peritoneal Mesothelioma. U.S. National Institutes of Health.
8	Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: US Preventive Services Task Force Recommendation Statement.JAMA. 2019 Aug 20;322(7):652-665. doi: 10.1001/jama.2019.10987.